Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

793

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Budesonide/formoterol (Symbicort® Turbuhaler®)

Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily

DRUG

Tiotropium (SpirivaTM)

Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily

Trial Locations (31)

Unknown

Research Site, Beijing

Research Site, Guangzhou

Research Site, Changsha

Research Site, Changchun

Research Site, Shenyang

Research Site, Shanghai

Research Site, Taiyuan

Research Site, Guangzhou

Research Site, Kowloon

Research Site, Hong Kong

Research Site, Hong Kong

Research Site, Jakarta

Research Site, Solo

Research Site, Surabaya

Research Site, Wŏnju

Research Site, Suwon

Research Site, Jinju

Research Site, Busan

Research Site, Daegu

Research Site, Gwangju

Research Site, Incheon

Research Site, Seoul

Research Site, Muang

Research Site, Nonthaburi

Research Site, Chiang Mai

Research Site, Bangkok

Research Site, Chon Buri

Research Site, Khon Kaen

Research Site, Phitsanulok

Research Site, Songkhla

Research Site, Udon Thani

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY